Search

Hutchison China MediTech Ltd ADR

Open

SectorHealthcare

11.59 0.96

Overview

Share price change

24h

Current

Min

10.9

Max

11.55

Key metrics

By Trading Economics

Income

7M

8M

Sales

3.7M

139M

P/E

Sector Avg

115.5

68.51

Profit margin

5.724

Employees

1,790

EBITDA

18M

4M

Recommendations

By TipRanks

Recommendations

Buy

12 Months Forecast

+25.58% upside

Market Stats

By TradingEconomics

Market Cap

95M

2B

Previous open

10.63

Previous close

11.59

News Sentiment

By Acuity

100%

0%

323 / 340 Ranking in Healthcare

Hutchison China MediTech Ltd ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

4 sie 2026, 23:56 UTC

News

Starbucks Corp raised its full-year EPS guidance to approximately $2.60, reflecting strong U.S. same-store sales growth. Shares are gaining in after-market trading.

4 sie 2026, 23:56 UTC

News

Alphabet Inc's market valuation is approximately $4.6 trillion, bolstered by strong second-quarter results. Shares traded higher in after-market hours, reflecting positive sentiment.

4 sie 2026, 23:56 UTC

News

Ameresco Inc reported second-quarter revenue of $515.5 million, a 9% increase year-over-year. Shares are trading higher in after-market hours following the results.

4 sie 2026, 23:56 UTC

News

Advanced Energy Industries reported record Q2 revenue of $574.1 million, leading to shares trading higher in after-market hours.

4 sie 2026, 23:51 UTC

News

Cooper-Standard Holdings will present at the J.P. Morgan 2026 Auto Conference on August 12, with a focus on business strategies. Shares traded little changed after hours.

4 sie 2026, 23:51 UTC

News

Teradata Corp shares fell in after-market hours following mixed Q2 results and disappointing Q3 guidance, projecting adjusted EPS of $0.55 to $0.59.

4 sie 2026, 23:51 UTC

News

8x8 Inc. shares are lower in after-market hours following mixed first-quarter results, with revenue exceeding expectations but second-quarter EPS guidance falling short.

4 sie 2026, 23:51 UTC

News

Hyster-Yale Materials Handling shares fell in after-market trading following a second-quarter revenue of $812.9 million and a net loss of $31.6 million.

4 sie 2026, 23:51 UTC

Social Media
News

Arista Networks shares higher in after-market hours following strong second-quarter results, with adjusted EPS of $1.02 and optimistic third-quarter guidance.

4 sie 2026, 23:51 UTC

News
Social Media

Hecla Mining Co reported second-quarter EPS of $0.17 and revenue of $333.85 million, exceeding expectations. Shares are higher in after-market trading.

4 sie 2026, 23:51 UTC

Correlated Moves
ETF Constituents
News
Macro News

Vanguard Information Technology ETF is trading higher in after-market hours, supported by strong earnings from tech stocks and positive sentiment from UBS's coupon payments.

4 sie 2026, 23:46 UTC

News

Teladoc Health faces scrutiny amid revenue miss and lowered outlook. Shares traded roughly flat in after-market hours following the developments.

4 sie 2026, 23:42 UTC

News

Apple Inc. seeks a preliminary injunction against OpenAI amid a legal battle, as shares trade higher in after-market hours.

4 sie 2026, 23:41 UTC

News

Shutterstock shares are higher in after-market hours despite a $155.9 million net loss and a $173.7 million goodwill impairment charge reported for Q2.

4 sie 2026, 23:41 UTC

News

Compass Inc. shares rise in after-market hours following strong Q2 revenue of $4.306 billion and optimistic Q3 guidance of $3.85 billion to $4.05 billion.

4 sie 2026, 23:41 UTC

News
Social Media

Lumen Technologies reported second-quarter revenue of $2.805 billion, exceeding estimates. Shares rose after hours as the company reaffirmed its full-year guidance.

4 sie 2026, 23:41 UTC

News

Flywire Corp reported strong Q2 results, with revenue surpassing estimates. Shares are higher in after-market trading following the raised full-year guidance.

4 sie 2026, 23:41 UTC

News

Community Healthcare Trust shares declined in after-market hours following second-quarter results that missed earnings and revenue expectations. EPS was $0.06 versus an estimated $0.12.

4 sie 2026, 23:41 UTC

News

Bruker shares higher in after-market hours following Jefferies' price target increase to $62.00, maintaining a Buy rating amid broader performance challenges.

4 sie 2026, 23:41 UTC

Social Media
News

Alphabet Inc shares are higher in after-market trading following the expansion of its Gemini feature in Google Classroom for K-12 users.

4 sie 2026, 23:41 UTC

News
Social Media

Zeta Global Holdings reported Q2 revenue of $443 million but shares fell in after-market trading amid mixed reactions and concerns over growth guidance.

4 sie 2026, 23:41 UTC

Social Media
News

Palantir Technologies reported strong second-quarter results but shares fell during after-market hours, overshadowed by broader market gains and mixed sentiment.

4 sie 2026, 23:41 UTC

Social Media
News

Rocket Lab USA Inc secures a $397 million contract from the U.S. Space Force, driving shares higher in after-market trading.

4 sie 2026, 23:41 UTC

News

IDEXX Laboratories reported second-quarter revenue of $1.22 billion, a 9.7% increase year-over-year. Shares are trading higher in after-market hours following the results.

4 sie 2026, 23:41 UTC

Social Media
News

Kratos Defense and Security Solutions reported Q2 revenues of $458.8 million, exceeding estimates. Shares are advancing in after-market trading amid raised sales guidance.

4 sie 2026, 23:36 UTC

News

EOG Resources reported strong Q2 earnings of $5.15 per share and revenues of $8.62 billion, contributing to shares trading higher in after-market hours.

4 sie 2026, 23:36 UTC

News

Alphatec Holdings shares fell in after-market trading following a net loss of $26 million, despite meeting adjusted EPS expectations and exceeding revenue forecasts.

4 sie 2026, 23:36 UTC

News

Dell Technologies reported nearly 40% of revenue now from AI initiatives. Shares are lower in after-market trading following the announcement.

4 sie 2026, 23:36 UTC

News

Marathon Petroleum shares higher in after-market trading, reflecting stable performance and a market capitalization of approximately $91.74 billion.

4 sie 2026, 23:36 UTC

News

Western Union has launched the Stablecard for international transfers, but shares are trading lower in after-market hours following routine trading activity.

Peer Comparison

Price change

Hutchison China MediTech Ltd ADR Forecast

Price Target

By TipRanks

25.58% upside

12 Months Forecast

Average 14.53 USD  25.58%

High 16 USD

Low 13.6 USD

Based on 3 Wall Street analysts offering 12 month price targets forHutchison China MediTech Ltd ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Buy

3 ratings

1

Buy

2

Hold

0

Sell

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Hutchison China MediTech Ltd ADR

HUTCHMED (China) Limited, together with its subsidiaries, discovers, develops, and commercializes targeted therapeutics and immunotherapies for cancer and immunological diseases in Hong Kong and internationally. The company develops Savolitinib for the treatment of non-small cell lung cancer (NSCLC), papillary renal cell carcinoma (RCC), and gastric cancer (GC); and Fruquintinib, an inhibitor for colorectal cancer (CRC), breast cancer, gastric cancer, microsatellite stable-CRC endometrial cancer (EMC), NSCLC, RCC, gastrointestinal, cervical, and solid tumors. It also develops Surufatinib, which is used for the treatment of pancreatic neuroendocrine tumor (NET), non-pancreatic NET, neuroendocrine carcinoma, SCLC, biliary tract cancer, and solid tumors; and Sovleplenib that treats hematological cancers and certain chronic immune diseases. In addition, it develops Tazemetostat for the treatment of certain epithelioid sarcoma and follicular lymphoma patients; HMPL-306, an inhibitor for hematological malignancies, gliomas, chondrosarcomas, cholangiocarcinomas, and solid tumors; HMPL-760, a Bruton's tyrosine kinase inhibitor; HMPL-453 for intrahepatic cholangiocarcinoma and solid tumors; HMPL-295 and HMPL-415 for solid tumors; HMPL-653 for metastatic solid tumors and tenosynovial giant cell tumors; and HMPL-A83 for the treatment of malignant neoplasms. It has collaboration agreements with AstraZeneca AB (publ), Lilly (Shanghai) Management Company Limited, Takeda, BeiGene Ltd., Inmagene Biopharmaceuticals Co. Ltd., Innovent Biologics Co., Inc., Genor Biopharma Co. Ltd., Shanghai Junshi Biosciences Co. Ltd., and Epizyme, Inc. The company was formerly known as Hutchison China MediTech Limited and changed its name to HUTCHMED (China) Limited in May 2021. HUTCHMED (China) Limited was incorporated in 2000 and is headquartered in Hong Kong, Hong Kong.
help-icon Live chat